Cornelia Lass-FlÃ¶rl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3806657/publications.pdf

Version: 2024-02-01

276	12,665	30070	36028
papers	citations	54 h-index	97 g-index

283	283	283	10905
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biofilm formation in clinically relevant filamentous fungi: a therapeutic challenge. Critical Reviews in Microbiology, 2022, 48, 197-221.	6.1	11
2	Sepsis in Pediatric Cancer: Does Gender Matter? A 20-Year Retrospective Study. Infectious Diseases and Therapy, 2022, 11, 581-585.	4.0	2
3	Wastewater surveillance of SARS-CoV-2 in Austria: development, implementation, and operation of the Tyrolean wastewater monitoring program. Journal of Water and Health, 2022, 20, 314-328.	2.6	11
4	Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. Journal of Antimicrobial Chemotherapy, 2022, 77, 1209-1210.	3.0	6
5	The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. Lancet Microbe, The, 2022, 3, e464-e470.	7.3	35
6	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. Journal of Allergy and Clinical Immunology, 2022, 149, 1242-1252.e12.	2.9	23
7	COVID-19 Associated Pulmonary Aspergillosis: Diagnostic Performance, Fungal Epidemiology and Antifungal Susceptibility. Journal of Fungi (Basel, Switzerland), 2022, 8, 93.	3.5	9
8	Candidemia Among Coronavirus Disease 2019 Patients in Turkey Admitted to Intensive Care Units: A Retrospective Multicenter Study. Open Forum Infectious Diseases, 2022, 9, ofac078.	0.9	13
9	Influence of Glucose on Candida albicans and the Relevance of the Complement FH-Binding Molecule Hgt1 in a Murine Model of Candidiasis. Antibiotics, 2022, 11, 257.	3.7	3
10	Aspergillus terreus and the Interplay with Amphotericin B: from Resistance to Tolerance?. Antimicrobial Agents and Chemotherapy, 2022, 66, e0227421.	3.2	11
11	Echinocandins and Their Activity against Aspergillus terreus Species Complex: a Novel Agar Screening Method. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0190921.	3.2	1
12	Multiple colony antifungal susceptibility testing detects polyresistance in clinical Candida cultures: an ECMM Excellence centers study. Clinical Microbiology and Infection, 2022, , .	6.0	6
13	Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 2330-2335.	1.3	1
14	Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opinion on Investigational Drugs, 2022, 31, 795-812.	4.1	23
15	Investigation of the effect of sustainable magnetic treatment on the microbiological communities in drinking water. Environmental Research, 2022, 213, 113638.	7.5	5
16	Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?. Journal of Antimicrobial Chemotherapy, 2021, 76, 418-422.	3.0	29
17	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	9.1	586
18	Rapid Antifungal Susceptibility Testing of Yeasts and Molds by MALDI-TOF MS: A Systematic Review and Meta-Analysis. Journal of Fungi (Basel, Switzerland), 2021, 7, 63.	3.5	12

#	Article	IF	Citations
19	Longitudinal Evaluation of Plasma Cytokine Levels in Patients with Invasive Candidiasis. Journal of Fungi (Basel, Switzerland), 2021, 7, 101.	3.5	3
20	Which Type of Empiric Antibiotic Therapy is Appropriate? A 20-Year Retrospective Study of Bloodstream Infections in Childhood Cancer. Infectious Diseases and Therapy, 2021, 10, 789-800.	4.0	7
21	The Environmental Spread of Aspergillus terreus in Tyrol, Austria. Microorganisms, 2021, 9, 539.	3.6	7
22	Dexamethasone Creates a Suppressive Microenvironment and Promotes Aspergillus fumigatus Invasion in a Human 3D Epithelial/Immune Respiratory Model. Journal of Fungi (Basel, Switzerland), 2021, 7, 221.	3.5	4
23	A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women. Frontiers in Microbiology, 2021, 12, 655069.	3.5	18
24	Clonal Candidemia Outbreak by Candida parapsilosis Carrying Y132F in Turkey: Evolution of a Persisting Challenge. Frontiers in Cellular and Infection Microbiology, 2021, 11, 676177.	3.9	34
25	ColdZyme Maintains Integrity in SARS-CoV-2-Infected Airway Epithelia. MBio, 2021, 12, .	4.1	15
26	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	8.2	106
27	Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 684014.	4.8	37
28	Aspergillus terreus Species Complex. Clinical Microbiology Reviews, 2021, 34, e0031120.	13.6	23
29	C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2â€“infected primary human airway epithelia. Journal of Allergy and Clinical Immunology, 2021, 147, 2083-2097.e6.	2.9	41
30	Pharmacokinetics and Antifungal Activity of Echinocandins in Ascites Fluid of Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, e0256520.	3.2	6
31	Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development. Cancers, 2021, 13, 3431.	3.7	21
32	Microbiological and Molecular Diagnosis of Mucormycosis: From Old to New. Microorganisms, 2021, 9, 1518.	3.6	38
33	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infectious Diseases, The, 2021, 21, e375-e386.	9.1	80
34	Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent Candida spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability. Antimicrobial Agents and Chemotherapy, 2021, 65, e0109321.	3.2	12
35	SARS-CoV-2â€“infected primary human airway epithelia illustrate mucus hypersecretion. Journal of Allergy and Clinical Immunology, 2021, 148, 909.	2.9	6
36	Serology anno 2021â€”fungal infections: from invasive to chronic. Clinical Microbiology and Infection, 2021, 27, 1230-1241.	6.0	52

#	Article	IF	Citations
37	Dexamethasone Promotes Aspergillus fumigatus Growth in Macrophages by Triggering M2 Repolarization via Targeting PKM2. Journal of Fungi (Basel, Switzerland), 2021, 7, 70.	3.5	12
38	Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium. Journal of Fungi (Basel, Switzerland), 2021, 7, 4.	3.5	5
39	MixInYeast: A Multicenter Study on Mixed Yeast Infections. Journal of Fungi (Basel, Switzerland), 2021, 7, 13.	3.5	14
40	The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs, 2021, 81, 1703-1729.	10.9	168
41	Complement Potentiates Immune Sensing of HIV-1 and Early Type I Interferon Responses. MBio, 2021, 12, e0240821.	4.1	6
42	Invasive Scedosporium spp. and Lomentospora prolificans infections in pediatric patients: Analysis of 55 cases from FungiScopeÂ® and the literature. International Journal of Infectious Diseases, 2020, 92, 114-122.	3.3	23
43	Recent Increase in the Prevalence of Fluconazole-Non-susceptible Candida tropicalis Blood Isolates in Turkey: Clinical Implication of Azole-Non-susceptible and Fluconazole Tolerant Phenotypes and Genotyping. Frontiers in Microbiology, 2020, 11, 587278.	3.5	21
44	Novel Antifungal Agents and Their Activity against Aspergillus Species. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462	3.5	17
45	Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement. Journal of Fungi (Basel, Switzerland), 2020, 6, 216.	3.5	21
46	First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant Candida parapsilosis Isolates Harboring Y132F and/or Y132F+K143R in Turkey. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	57
47	Comparative immunopathogenesis in a murine model of inhalative infection with the mucormycetes Lichtheimia corymbifera and Rhizopus arrhizus. PLoS ONE, 2020, 15, e0234063.	2.5	6
48	Candida and Complement: New Aspects in an Old Battle. Frontiers in Immunology, 2020, 11, 1471.	4.8	21
49	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScopeâ“‡â€”Global Registry for Emerging Fungal Infections. Journal of Infection, 2020, 81, 802-815.	3.3	20
50	Aspergillus-Derived Galactosaminogalactan Triggers Complement Activation on Human Platelets. Frontiers in Immunology, 2020, 11, 550827.	4.8	6
51	The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens. Journal of Fungi (Basel, Switzerland), 2020, 6, 138.	3.5	84
52	Efficacy of LAMB against Emerging Azole- and Multidrug-Resistant Candida parapsilosis Isolates in the Galleria mellonella Model. Journal of Fungi (Basel, Switzerland), 2020, 6, 377.	3.5	14
53	Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium. Antibiotics, 2020, 9, 877.	3.7	125
54	Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity. Frontiers in Immunology, 2020, 11, 572114.	4.8	2

#	Article	IF	Citations
55	Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe, The, 2020, 1, e53-e55.	7.3	158
56	Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure. Mycoses, 2020, 63, 911-920.	4.0	34
57	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	8.2	278
58	Development and Validation of a Rapid, Single-Step Reverse Transcriptase Loop-Mediated Isothermal Amplification (RT-LAMP) System Potentially to Be Used for Reliable and High-Throughput Screening of COVID-19. Frontiers in Cellular and Infection Microbiology, 2020, 10, 331.	3.9	113
59	Clinical Usefulness of Susceptibility Breakpoints for Yeasts in the Treatment of Candidemia: A Noninterventional Study. Journal of Fungi (Basel, Switzerland), 2020, 6, 76.	3.5	3
60	Evaluation of Molecular Epidemiology, Clinical Characteristics, Antifungal Susceptibility Profiles, and Molecular Mechanisms of Antifungal Resistance of Iranian Candida parapsilosis Species Complex Blood Isolates. Frontiers in Cellular and Infection Microbiology, 2020, 10, 206.	3.9	44
61	European confederation of medical mycology expert consultâ€"An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	4.0	8
62	Immunotherapy as an Antifungal Strategy in Immune Compromised Hosts. Current Clinical Microbiology Reports, 2020, 7, 57-66.	3.4	3
63	COVID-19 Associated Pulmonary Aspergillosis (CAPA)â€"From Immunology to Treatment. Journal of Fungi (Basel, Switzerland), 2020, 6, 91.	3.5	292
64	Benefits of riskâ€adapted and mouldâ€specific antifungal prophylaxis in childhood leukaemia. British Journal of Haematology, 2020, 191, 816-824.	2.5	14
65	Galactosaminogalactan secreted from Aspergillus fumigatus and Aspergillus flavus induces platelet activation. Microbes and Infection, 2020, 22, 331-339.	1.9	9
66	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWPâ€EBMT, EORTCâ€IDG and SEIFEM survey. Mycoses, 2020, 63, 420-429.	4.0	7
67	Antifungal susceptibility testing in Candida species: current methods and promising new tools for shortening the turnaround time. Expert Review of Anti-Infective Therapy, 2020, 18, 779-787.	4.4	12
68	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. Journal of Antimicrobial Chemotherapy, 2020, 75, 1807-1819.	3.0	37
69	Candida tropicalis is the most prevalent yeast species causing candidemia in Algeria: the urgent need for antifungal stewardship and infection control measures. Antimicrobial Resistance and Infection Control, 2020, 9, 50.	4.1	39
70	Immunological response to COVID-19 and its role as a predisposing factor in invasive aspergillosis. Current Medical Mycology, 2020, 6, 75-79.	0.8	5
71	Elevated minimum inhibitory concentrations to antifungal drugs prevail in 14 rare species of candidemia-causing Saccharomycotina yeasts. Medical Mycology, 2020, 58, 987-995.	0.7	14
72	Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?. Journal of Fungi (Basel, Switzerland), 2020, 6, 66.	3.5	43

#	Article	IF	Citations
73	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) â€“ a multicenter study. Open Forum Infectious Diseases, 2020, 7, S795-S796.	0.9	0
74	Galleria mellonella as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment. Medical Mycology, 2019, 57, 351-362.	0.7	54
75	Cryptic species of Aspergillus section Terrei display essential physiological features to cause infection and are similar in their virulence potential in Galleria mellonella. Virulence, 2019, 10, 542-554.	4.4	14
76	Hypoxia Decreases Diagnostic Biomarkers for Aspergillosis In Vitro. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 Tc	3.5	1
77	Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology. Transplant Infectious Disease, 2019, 21, e13141.	1.7	24
78	Anidulafungin Susceptibility Testing of Candida glabrata Isolates from Blood Cultures by the MALDI Biotyper Antibiotic (Antifungal) Susceptibility Test Rapid Assay. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	17
79	Defining breakthrough invasive fungal infectionâ€“Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses, 2019, 62, 716-729.	4.0	129
80	ECMM CandiRegâ€”A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	4.0	19
81	Evaluation of a Novel Mitochondrial Pan-Mucorales Marker for the Detection, Identification, Quantification, and Growth Stage Determination of Mucormycetes. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	3.5	10
82	Diagnostic Performance of a Novel Multiplex PCR Assay for Candidemia among ICU Patients. Journal of Fungi (Basel, Switzerland), 2019, 5, 86.	3.5	19
83	Antibiotic resistance of blood cultures in regional and tertiary hospital settings of Tyrol, Austria (2006-2015): Impacts & trends. PLoS ONE, 2019, 14, e0223467.	2.5	6
84	The leucine biosynthetic pathway is crucial for adaptation to iron starvation and virulence in Aspergillus fumigatus. Virulence, 2019, 10, 925-934.	4.4	23
85	Turning the World Upside-Down in Cellulose for Improved Culturing and Imaging of Respiratory Challenges within a Human 3D Model. Cells, 2019, 8, 1292.	4.1	14
86	The Emergence of Rare Clinical Aspergillus Species in Qatar: Molecular Characterization and Antifungal Susceptibility Profiles. Frontiers in Microbiology, 2019, 10, 1677.	3.5	22
87	Minimal Inhibitory Concentration (MIC)-Phenomena in Candida albicans and Their Impact on the Diagnosis of Antifungal Resistance. Journal of Fungi (Basel, Switzerland), 2019, 5, 83.	3.5	10
88	Galactosaminogalactan (GAG) and its multiple roles in Aspergillus pathogenesis. Virulence, 2019, 10, 976-983.	4.4	52
89	Candida albicans Factor H Binding Molecule Hgt1p â€“ A Low Glucose-Induced Transmembrane Protein Is Trafficked to the Cell Wall and Impairs Phagocytosis and Killing by Human Neutrophils. Frontiers in Microbiology, 2019, 9, 3319.	3.5	24
90	Antifungal susceptibility profiles of rare ascomycetous yeasts. Journal of Antimicrobial Chemotherapy, 2019, 74, 2649-2656.	3.0	22

#	Article	IF	Citations
91	Antifungal resistance in Aspergillus terreus: A current scenario. Fungal Genetics and Biology, 2019, 131, 103247.	2.1	27
92	Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans. Frontiers in Immunology, 2019, 10, 890.	4.8	16
93	The changing spectrum of Saccharomycotina yeasts causing candidemia: phylogeny mirrors antifungal susceptibility patterns for azole drugs and amphothericin B. FEMS Yeast Research, 2019, 19, .	2.3	30
94	Co- but not Sequential Infection of DCs Boosts Their HIV-Specific CTL-Stimulatory Capacity. Frontiers in Immunology, 2019, 10, 1123.	4.8	1
95	Precise genome editing using a CRISPR-Cas9 method highlights the role of CoERG11 amino acid substitutions in azole resistance in Candida orthopsilosis. Journal of Antimicrobial Chemotherapy, 2019, 74, 2230-2238.	3.0	20
96	Whole-Genome Sequencing of the Opportunistic Yeast Pathogen Candida inconspicua Uncovers Its Hybrid Origin. Frontiers in Genetics, 2019, 10, 383.	2.3	63
97	How to make a fast diagnosis in invasive aspergillosis. Medical Mycology, 2019, 57, S155-S160.	0.7	55
98	Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1704-1712.	3.0	25
99	2104. Susceptibility Trends in Antifungal Resistance (STAR) Study: Preliminary Data from A New Prospective Antifungal Surveillance Study. Open Forum Infectious Diseases, 2019, 6, S712-S712.	0.9	0
100	Genome Assemblies of Two Rare Opportunistic Yeast Pathogens:Diutina rugosa(syn.Candida) Tj ETQq0 0 0 rgBT /Overlock 10 Genetics, 2019, 9, 3921-3927.	1.8	6
101	2268. Clinical Implications of Azole-Resistant vs. Azole-Susceptible Invasive Aspergillosis in Hematological Malignancy (CLARITY): A Multicenter Study. Open Forum Infectious Diseases, 2019, 6, S776-S776.	0.9	0
102	Immune Parameters for Diagnosis and Treatment Monitoring in Invasive Mold Infection. Journal of Fungi (Basel, Switzerland), 2019, 5, 116.	3.5	12
103	<i>Candida</i>: Platelet Interaction and Platelet Activity in vitro. Journal of Innate Immunity, 2019, 11, 52-62.	3.8	17
104	High percentage of microbial colonization of osteosynthesis material in clinically unremarkable patients. MicrobiologyOpen, 2019, 8, e00658.	3.0	16
105	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <scp>FUN</scp>gal infections Definitions in <scp>ICU</scp> patients (<scp>FUNDICU</scp>) project. Mycoses, 2019, 62, 310-319.	4.0	53
106	Antifungal susceptibility of yeast bloodstream isolates collected during a 10â€year period in Austria. Mycoses, 2019, 62, 357-367.	4.0	16
107	Î²-1,3-glucan-lackingAspergillus fumigatusmediates an efficient antifungal immune response by activating complement and dendritic cells. Virulence, 2019, 10, 957-969.	4.4	13
108	Novel multiplex real-time quantitative PCR detecting system approach for direct detection of Candida auris and its relatives in spiked serum samples. Future Microbiology, 2019, 14, 33-45.	2.0	38

#	Article	IF	Citations
109	YEAST PANEL multiplex PCR for identification of clinically important yeast species: stepwise diagnostic strategy, useful for developing countries. Diagnostic Microbiology and Infectious Disease, 2019, 93, 112-119.	1.8	42
110	A Retrospective Assessment of Four Antigen Assays for the Detection of Invasive Candidiasis Among High-Risk Hospitalized Patients. Mycopathologia, 2018, 183, 513-519.	3.1	13
111	EQUAL Candida Score: An <scp>ECMM</scp> score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management. Mycoses, 2018, 61, 326-330.	4.0	60
112	Aspergillus terreus: Novel lessons learned on amphotericin B resistance. Medical Mycology, 2018, 56, S73-S82.	0.7	50
113	In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex. Mycoses, 2018, 61, 134-142.	4.0	29
114	Generation of A Mucor circinelloides Reporter Strainâ€"A Promising New Tool to Study Antifungal Drug Efficacy and Mucormycosis. Genes, 2018, 9, 613.	2.4	16
115	Azole-resistant and -susceptible Aspergillus fumigatus isolates show comparable fitness and azole treatment outcome in immunocompetent mice. Medical Mycology, 2018, 56, 703-710.	0.7	8
116	Outbreak report: a nosocomial outbreak of vancomycin resistant enterococci in a solid organ transplant unit. Antimicrobial Resistance and Infection Control, 2018, 7, 86.	4.1	16
117	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	3.5	66
118	A nationwide passive surveillance on fungal infections shows a low burden of azole resistance in molds and yeasts in Tyrol, Austria. Infection, 2018, 46, 701-704.	4.7	11
119	Proof of Concept for MBT ASTRA, a Rapid Matrix-Assisted Laser Desorption Ionizationâ€"Time of Flight Mass Spectrometry (MALDI-TOF MS)-Based Method To Detect Caspofungin Resistance in Candida albicans and Candida glabrata. Journal of Clinical Microbiology, 2018, 56, .	3.9	52
120	Sterol Composition of Clinically Relevant Mucorales and Changes Resulting from Posaconazole Treatment. Molecules, 2018, 23, 1218.	3.8	15
121	Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei. Journal of Antimicrobial Chemotherapy, 2018, 73, 3068-3073.	3.0	32
122	Treatment of Infections Due to Aspergillus terreus Species Complex. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 T	3.5	30
123	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses, 2018, 61, 885-894.	4.0	52
124	Control of hospital-acquired infections in Austria. Wiener Klinische Wochenschrift, 2018, 130, 673-679.	1.9	0
125	Voriconazole MICs are predictive for the outcome of experimental disseminated scedosporiosis. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw532.	3.0	14
126	Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What isAspergillus?. Medical Mycology, 2017, 55, myw093.	0.7	24

#	Article	IF	Citations
127	Pan-azole-resistantCandida tropicaliscarrying homozygouserg11mutations at position K143R: a new emerging superbug?. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw558.	3.0	35
128	A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis. Nature Communications, 2017, 8, 14017.	12.8	110
129	Promising immunotherapy against fungal diseases. Expert Opinion on Biological Therapy, 2017, 17, 861-870.	3.1	22
130	Improving outcome of fungal diseases â€“ Guiding experts and patients towards excellence. Mycoses, 2017, 60, 420-425.	4.0	61
131	Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	19
132	Changes in the epidemiological landscape of invasive mould infections and disease. Journal of Antimicrobial Chemotherapy, 2017, 72, i5-i11.	3.0	82
133	IL-10 overexpression predisposes to invasive aspergillosis by suppressing antifungal immunity. Journal of Allergy and Clinical Immunology, 2017, 140, 867-870.e9.	2.9	37
134	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 2017, 102, 433-444.	3.5	468
135	Nosocomial outbreak of extensively drug-resistant Pseudomonas aeruginosa associated with aromatherapy. American Journal of Infection Control, 2017, 45, 453-455.	2.3	6
136	Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience. Infection, 2017, 45, 867-875.	4.7	19
137	Impact of Morphological Sectors on Antifungal Susceptibility Testing and Virulence Studies. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	7
138	Invasive candidiasis: future directions in non-culture based diagnosis. Expert Review of Anti-Infective Therapy, 2017, 15, 829-838.	4.4	18
139	Oxidative Stress Response Tips the Balance in Aspergillus terreus Amphotericin B Resistance. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	29
140	Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14Î±-demethylase. Scientific Reports, 2017, 7, 15898.	3.3	59
141	Commercial Molecular Tests for Fungal Diagnosis from a Practical Point of View. Methods in Molecular Biology, 2017, 1508, 85-105.	0.9	10
142	Current Challenges in the Diagnosis of Fungal Infections. Methods in Molecular Biology, 2017, 1508, 3-15.	0.9	31
143	Salmonella Utilizes Zinc To Subvert Antimicrobial Host Defense of Macrophages via Modulation of NF-ÎºB Signaling. Infection and Immunity, 2017, 85, .	2.2	28
144	Long term complications following 54 consecutive lung transplants. Journal of Thoracic Disease, 2016, 8, 1234-1244.	1.4	20

#	Article	IF	Citations
145	Common Genetic Polymorphisms within NFÎºB-Related Genes and the Risk of Developing Invasive Aspergillosis. Frontiers in Microbiology, 2016, 7, 1243.	3.5	13
146	Granulomatous encephalitis: protothecosis excluded?. Histopathology, 2016, 69, 1082-1084.	2.9	5
147	In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method. Diagnostic Microbiology and Infectious Disease, 2016, 85, 438-443.	1.8	45
148	Lichtheimia Infection in a Lymphoma Patient: Case Report and a Brief Review of the Available Diagnostic Tools. Mycopathologia, 2016, 181, 561-566.	3.1	6
149	Natural killer cellâ€mediated damage of clinical isolates of mucormycetes. Mycoses, 2016, 59, 34-38.	4.0	34
150	IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. Nature Communications, 2016, 7, 10791.	12.8	201
151	Generation of Human Monocyte-derived Dendritic Cells from Whole Blood. Journal of Visualized Experiments, 2016, , .	0.3	44
152	A point prevalence survey on hand hygiene, with a special focus onÂCandida species. American Journal of Infection Control, 2016, 44, 71-73.	2.3	17
153	Isavuconazole: an orphan drug for treating invasive candidiasis. Expert Opinion on Orphan Drugs, 2016, 4, 333-342.	0.8	2
154	Invasive pulmonary Aspergillosis in organ transplants â€“ Focus on lung transplants. Respiratory Investigation, 2016, 54, 76-84.	1.8	31
155	Clinical evaluation of a Mucorales-specific real-time PCR assay in tissue and serum samples. Journal of Medical Microbiology, 2016, 65, 1414-1421.	1.8	62
156	Aspergillus fumigatus responds to natural killer (NK) cells with upregulation of stress related genes and inhibits the immunoregulatory function of NK cells. Oncotarget, 2016, 7, 71062-71071.	1.8	21
157	Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses, 2015, 58, 2-13.	4.0	314
158	Advances in the management of fungal infections. Mycoses, 2015, 58, 1-1.	4.0	5
159	Diagnostic accuracy of the Aspergillusâ€specific bronchoalveolar lavage lateralâ€flow assay in haematological malignancy patients. Mycoses, 2015, 58, 461-469.	4.0	51
160	Bronchoalveolar Lavage Fluid (1,3)Î²-D-Glucan for the Diagnosis of Invasive Fungal Infections in Solid Organ Transplantation. Transplantation, 2015, 99, e140-e144.	1.0	37
161	Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells. PLoS Pathogens, 2015, 11, e1005005.	4.7	44
162	In Vitro Activities of Amphotericin B, Terbinafine, and Azole Drugs against Clinical and Environmental Isolates of Aspergillus terreus Sensu Stricto. Antimicrobial Agents and Chemotherapy, 2015, 59, 3619-3622.	3.2	9

#	Article	IF	Citations
163	Aspergillus-Specific Lateral-Flow Device and Real-Time PCR Testing of Bronchoalveolar Lavage Fluid: a Combination Biomarker Approach for Clinical Diagnosis of Invasive Pulmonary Aspergillosis. Journal of Clinical Microbiology, 2015, 53, 2103-2108.	3.9	45
164	Immediate T-Helper 17 Polarization Upon Triggering CD11b/c on HIV-Exposed Dendritic Cells. Journal of Infectious Diseases, 2015, 212, 44-56.	4.0	22
165	Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: realâ€life data from a retrospective singleâ€centre observational study. European Journal of Haematology, 2015, 94, 258-264.	2.2	35
166	Galleria mellonellaas a host model to studyAspergillus terreusvirulence and amphotericin B resistance. Virulence, 2015, 6, 591-598.	4.4	54
167	Amphotericin B Resistance in Aspergillus terreus Is Overpowered by Coapplication of Pro-oxidants. Antioxidants and Redox Signaling, 2015, 23, 1424-1438.	5.4	25
168	Susceptibility Profiles of Amphotericin B and Posaconazole against Clinically Relevant Mucorales Species under Hypoxic Conditions. Antimicrobial Agents and Chemotherapy, 2015, 59, 1344-1346.	3.2	15
169	Multidrug- and Cross-Resistant Candida: the Looming Threat. Current Fungal Infection Reports, 2015, 9, 23-36.	2.6	3
170	Necrotizing mycosis due to Verruconis gallopava in an immunocompetent patient. Infection, 2015, 43, 743-746.	4.7	13
171	Complement and platelets: Mutual interference in the immune network. Molecular Immunology, 2015, 67, 108-118.	2.2	62
172	Differential gene expression in Aspergillus fumigatus induced by human platelets in vitro. International Journal of Medical Microbiology, 2015, 305, 327-338.	3.6	9
173	Effect of Reduced Oxygen on the Antifungal Susceptibility of Clinically Relevant Aspergilli. Antimicrobial Agents and Chemotherapy, 2015, 59, 1806-1810.	3.2	12
174	Etest Cannot Be Recommended for In Vitro Susceptibility Testing of Mucorales. Antimicrobial Agents and Chemotherapy, 2015, 59, 3663-3665.	3.2	29
175	Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. Critical Care, 2015, 19, 178.	5.8	65
176	Biliary amphotericin B pharmacokinetics and pharmacodynamics in critically ill liver transplant recipients receiving treatment with amphotericin B lipid formulations. International Journal of Antimicrobial Agents, 2015, 46, 325-331.	2.5	7
177	Blocking Hsp70 Enhances the Efficiency of Amphotericin B Treatment against Resistant Aspergillus terreus Strains. Antimicrobial Agents and Chemotherapy, 2015, 59, 3778-3788.	3.2	40
178	Treatment of drug-resistantAspergillusinfection. Expert Opinion on Pharmacotherapy, 2015, 16, 2267-2270.	1.8	19
179	Phylogenetic diversity of human pathogenic Fusarium and emergence of uncommon virulent species. Journal of Infection, 2015, 71, 658-666.	3.3	35
180	1462Bronchoalveolar Lavage Lateral-Flow Device Test for Diagnosing Invasive Pulmonary Aspergillosis in ICU patients: a multicenter study. Open Forum Infectious Diseases, 2014, 1, S385-S386.	0.9	1

#	Article	IF	Citations
181	Laboratory diagnosis of mucormycosis: current status and future perspectives. Future Microbiology, 2014, 9, 683-695.	2.0	105
182	De Novo Whole-Genome Sequence and Genome Annotation of Lichtheimia ramosa. Genome Announcements, 2014, 2, .	0.8	27
183	Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis in Solid Organ Transplant Patients. Transplantation, 2014, 98, 898-902.	1.0	54
184	Proposed nomenclature for Pseudallescheria, Scedosporium and related genera. Fungal Diversity, 2014, 67, 1-10.	12.3	152
185	EUCAST Testing of Isavuconazole Susceptibility in Aspergillus: Comparison of Results for Inoculum Standardization Using Conidium Counting versus Optical Density. Antimicrobial Agents and Chemotherapy, 2014, 58, 6432-6436.	3.2	12
186	Computed tomography guided percutaneous lung biopsies and suspected fungal infections in pediatric cancer patients. Pediatric Blood and Cancer, 2014, 61, 1620-1624.	1.5	9
187	<scp>EUCAST</scp> Technical Note on Candida and micafungin, anidulafungin and fluconazole. Mycoses, 2014, 57, 377-379.	4.0	38
188	Assessing micafungin/triazole combinations for the treatment of invasive scedosporiosis due to Scedosporium apiospermum and Scedosporium boydii. Journal of Antimicrobial Chemotherapy, 2014, 69, 3027-3032.	3.0	16
189	In Vitro Antifungal Susceptibility of Candida glabrata to Caspofungin and the Presence of FKS Mutations Correlate with Treatment Response in an Immunocompromised Murine Model of Invasive Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3646-3649.	3.2	10
190	Platelet immunology in fungal infections. Thrombosis and Haemostasis, 2014, 112, 632-639.	3.4	49
191	Incidence of Cyp51 A Key Mutations in Aspergillus fumigatusâ€"A Study on Primary Clinical Samples of Immunocompromised Patients in the Period of 1995â€"2013. PLoS ONE, 2014, 9, e103113.	2.5	44
192	Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility. Medical Microbiology and Immunology, 2013, 202, 379-389.	4.8	14
193	Why is biopsy of suspected fungal lung lesions necessary?. Medical Mycology Case Reports, 2013, 2, 141-143.	1.3	4
194	Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.. Drug Resistance Updates, 2013, 16, 81-95.	14.4	106
195	Minireview: host defence in invasive aspergillosis. Mycoses, 2013, 56, 403-413.	4.0	66
196	New Insight into Amphotericin B Resistance in Aspergillus terreus. Antimicrobial Agents and Chemotherapy, 2013, 57, 1583-1588.	3.2	62
197	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica, 2013, 98, e127-e130.	3.5	99
198	Utility of PCR in Diagnosis of Invasive Fungal Infections: Real-Life Data from a Multicenter Study. Journal of Clinical Microbiology, 2013, 51, 863-868.	3.9	54

#	Article	IF	Citations
199	Interaction of Platelets and Anidulafungin against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2013, 57, 626-628.	3.2	11
200	Determination of Isavuconazole Susceptibility of Aspergillus and Candida Species by the EUCAST Method. Antimicrobial Agents and Chemotherapy, 2013, 57, 5426-5431.	3.2	64
201	The <scp>M</scp>editerranean red alga <scp>A</scp>sparagopsis taxiformis has antifungal activity against Aspergillus species. Mycoses, 2013, 56, 516-519.	4.0	21
202	Rep-PCR and RAPD-PCR fingerprinting ofAspergillus terreus. Medical Mycology, 2013, 51, 876-879.	0.7	8
203	Invasive Pulmonary Mycosis Due to Penicillium chrysogenum. Transplantation, 2013, 95, e21-e23.	1.0	27
204	Up-date on Diagnostic Strategies of Invasive Aspergillosis. Current Pharmaceutical Design, 2013, 19, 3595-3614.	1.9	50
205	New Insights into Invasive Aspergillosis - from the Pathogen to the Disease. Current Pharmaceutical Design, 2013, 19, 3679-3688.	1.9	29
206	Characterization of the Cellular Immune Responses to Rhizopus oryzae With Potential Impact on Immunotherapeutic Strategies in Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases, 2012, 206, 135-139.	4.0	31
207	In Vivo Emergence of Aspergillus terreus with Reduced Azole Susceptibility and a Cyp51a M217I Alteration. Journal of Infectious Diseases, 2012, 206, 981-985.	4.0	55
208	Aspergillus terreus: How Inoculum Size and Host Characteristics Affect Its Virulence. Journal of Infectious Diseases, 2012, 205, 1192-1194.	4.0	11
209	What paths are open for tackling increasing azole resistance inAspergillusin the clinic?. Expert Review of Anti-Infective Therapy, 2012, 10, 1229-1231.	4.4	0
210	Susceptibility Screening of Hyphae-Forming Fungi with a New, Easy, and Fast Inoculum Preparation Method. Mycopathologia, 2012, 174, 467-474.	3.1	7
211	Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. Journal of Antimicrobial Chemotherapy, 2012, 67, 2268-2273.	3.0	131
212	EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clinical Microbiology and Infection, 2012, 18, E246-E247.	6.0	368
213	Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. Journal of Allergy and Clinical Immunology, 2012, 130, 1368-1374.e2.	2.9	33
214	Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an <scp>A</scp>spergillus <scp>PCR</scp> assay and a galactomannan <scp>ELISA</scp> in bronchoalveolar lavage samples. European Journal of Haematology, 2012, 89, 120-127.	2.2	63
215	High-frequency Triazole Resistance Found In Nonculturable Aspergillus fumigatus from Lungs of Patients with Chronic Fungal Disease. Clinical Infectious Diseases, 2011, 52, 1123-1129.	5.8	264
216	Triazole Antifungal Agents in Invasive Fungal Infections. Drugs, 2011, 71, 2405-2419.	10.9	217

#	Article	IF	Citations
217	Detection and investigation of invasive mould disease. Journal of Antimicrobial Chemotherapy, 2011, 66, i15-i24.	3.0	111
218	EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS IN THE MEDITERRANEAN AREA. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011016.	1.3	43
219	Current evidence for the treatment of invasive fungal infections in immunocompromised patients. Clinical Investigation, 2011, 1, 447-457.	0.0	3
220	Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease - review of the literature. European Journal of Medical Research, 2011, 16, 153.	2.2	56
221	Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. Current Fungal Infection Reports, 2011, 5, 128-134.	2.6	5
222	Nonâ€“Culture-Based Methods for the Diagnosis of Invasive Candidiasis. Current Fungal Infection Reports, 2011, 5, 151-156.	2.6	0
223	Biopsy Procedures for Molecular Tissue Diagnosis of Invasive Fungal Infections. Current Infectious Disease Reports, 2011, 13, 504-509.	3.0	11
224	Platelets enhance activity of antimycotic substances against non-Aspergillus fumigatus Aspergillusspeciesin vitro. Medical Mycology, 2011, 49, 157-166.	0.7	13
225	Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey. Medical Mycology, 2011, 49, 856-863.	0.7	16
226	Candida albicans Hgt1p, a Multifunctional Evasion Molecule: Complement Inhibitor, CR3 Analogue, and Human Immunodeficiency Virusâ€“Binding Molecule. Journal of Infectious Diseases, 2011, 204, 802-809.	4.0	41
227	Epidemiology of invasive fungal infections in the mediterranean area. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e20110016.	1.3	16
228	In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?. Current Infectious Disease Reports, 2010, 12, 401-408.	3.0	11
229	In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses, 2010, 53, 1-11.	4.0	51
230	Environmental Study of Azole-Resistant Aspergillus fumigatus and Other Aspergilli in Austria, Denmark, and Spain. Antimicrobial Agents and Chemotherapy, 2010, 54, 4545-4549.	3.2	217
231	Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Review of Anti-Infective Therapy, 2010, 8, 127-135.	4.4	20
232	In vitro susceptibility testing in Aspergillus species: an update. Future Microbiology, 2010, 5, 789-799.	2.0	32
233	EUCAST breakpoints for antifungals. Drug News and Perspectives, 2010, 23, 93.	1.5	40
234	In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrobial Agents and Chemotherapy, 2009, 53, 1645-1647.	3.2	77

#	Article	IF	Citations
235	Diagnosing invasive fungal diseases â€“ limitations of microbiological diagnostic methods. Expert Opinion on Medical Diagnostics, 2009, 3, 461-470.	1.6	15
236	Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing. Antimicrobial Agents and Chemotherapy, 2009, 53, 1185-1193.	3.2	110
237	Diagnosing Aspergillosis: The Role of Invasive Diagnostic Interventions. , 2009, , 391-405.		0
238	In Vitro Activities of Various Antifungal Drugs against Aspergillus terreus : Global Assessment Using the Methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrobial Agents and Chemotherapy, 2009, 53, 794-795.	3.2	62
239	Aspergillus alabamensis , a New Clinically Relevant Species in the Section Terrei. Eukaryotic Cell, 2009, 8, 713-722.	3.4	67
240	Azole resistance in aspergillosis: The next threat?. Current Fungal Infection Reports, 2009, 3, 236-242.	2.6	9
241	The changing face of epidemiology of invasive fungal disease in Europe. Mycoses, 2009, 52, 197-205.	4.0	351
242	Triazole-resistant candidaemia following posaconazole exposure. International Journal of Antimicrobial Agents, 2009, 33, 494-495.	2.5	11
243	Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. International Journal of Hematology, 2008, 88, 508-515.	1.6	94
244	In vitro susceptibilityâ€testing in Aspergillus species. Mycoses, 2008, 51, 437-446.	4.0	22
245	First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation. Diagnostic Microbiology and Infectious Disease, 2008, 62, 336-339.	1.8	28
246	Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrobial Agents and Chemotherapy, 2008, 52, 3637-3641.	3.2	138
247	Human Platelets AttenuateAspergillusSpecies via Granuleâ€Dependent Mechanisms. Journal of Infectious Diseases, 2008, 198, 1243-1246.	4.0	71
248	Establishing In Vitro-In Vivo Correlations for Aspergillus fumigatus : the Challenge of Azoles versus Echinocandins. Antimicrobial Agents and Chemotherapy, 2008, 52, 3504-3511.	3.2	98
249	Reply to Garzoni and Dumont. Clinical Infectious Diseases, 2008, 46, 784-785.	5.8	3
250	Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro. Antimicrobial Agents and Chemotherapy, 2008, 52, 2636-2638.	3.2	62
251	Susceptibility Testing of Anidulafungin and Voriconazole Alone and in Combination against Conidia and Hyphae of Aspergillus spp. under Hypoxic Conditions. Antimicrobial Agents and Chemotherapy, 2008, 52, 1873-1875.	3.2	26
252	Potential Basis for Amphotericin B Resistance in Aspergillus terreus. Antimicrobial Agents and Chemotherapy, 2008, 52, 1553-1555.	3.2	116

#	Article	IF	Citations
253	Molecular Typing of Aspergillus terreus Isolates Collected in Houston, Texas, and Innsbruck, Austria: Evidence of Great Genetic Diversity. Journal of Clinical Microbiology, 2007, 45, 2686-2690.	3.9	49
254	Human Protothecosis. Clinical Microbiology Reviews, 2007, 20, 230-242.	13.6	272
255	Posaconazole Enhances the Activity of Amphotericin B against Aspergillus Hyphae In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 791-793.	3.2	23
256	The Value of Computed Tomography-Guided Percutaneous Lung Biopsy for Diagnosis of Invasive Fungal Infection in Immunocompromised Patients. Clinical Infectious Diseases, 2007, 45, e101-e104.	5.8	200
257	Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial. Expert Review of Anti-Infective Therapy, 2007, 5, 929-932.	4.4	3
258	Interaction of 5-hydroxytryptamine (serotonin) against Aspergillus spp. in vitro. International Journal of Antimicrobial Agents, 2007, 29, 424-429.	2.5	16
259	Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiology Letters, 2006, 151, 263-268.	1.8	78
260	Clinical evaluation of Aspergillus-PCR for detection of invasive aspergillosis in immunosuppressed patients. Klinische Bewertung der Aspergillus-PCR zum Nachweis der invasiven Aspergillose bei immunsupprimierten Patienten. Mycoses, 2005, 48, 12-17.	4.0	30
261	Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. British Journal of Haematology, 2005, 131, 201-207.	2.5	252
262	In Vitro Activities of Amphotericin B and Voriconazole against Aleurioconidia from Aspergillus terreus. Antimicrobial Agents and Chemotherapy, 2005, 49, 2539-2540.	3.2	20
263	Diagnosing Invasive Aspergillosis during Antifungal Therapy by PCR Analysis of Blood Samples. Journal of Clinical Microbiology, 2004, 42, 4154-4157.	3.9	107
264	Disseminated Infection with Prototheca zopfii after Unrelated Stem Cell Transplantation for Leukemia. Journal of Clinical Microbiology, 2004, 42, 4907-4908.	3.9	48
265	The role of complement in invasive fungal infections. Die Rolle des Komplements bei invasiven Pilzinfektionen. Mycoses, 2004, 47, 93-103.	4.0	25
266	Interaction of sertraline withCandidaspecies selectively attenuates fungal virulence in vitro. FEMS Immunology and Medical Microbiology, 2003, 35, 11-15.	2.7	25
267	Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method. International Journal of Antimicrobial Agents, 2003, 21, 229-233.	2.5	27
268	Diagnosing and monitoring of invasive aspergillosis during antifungal therapy by polymerase chain reaction: an experimental study in mice. Diagnostic Microbiology and Infectious Disease, 2003, 47, 569-572.	1.8	21
269	Antifungal properties of 5-hydroxytryptamine (serotonin) against Candida species in vitro. Journal of Medical Microbiology, 2003, 52, 169-171.	1.8	19
270	Short Communication - Antifungal properties of 5-hydroxytryptamine (serotonin) against Aspergillus spp. in vitro. International Journal of Medical Microbiology, 2002, 291, 655-657.	3.6	22

#	Article	IF	Citations
271	In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae . In vitro-Empfindlichkeit von Aspergillus-Konidien und -Hyphen gegenuber Amphotericin B und Amphotericin B-Lipidpraparationen. Mycoses, 2002, 45, 166-169.	4.0	18
272	Helicobacter pylori infection and neopterin. Pteridines, 2001, 12, 126-129.	0.5	5
273	Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. British Journal of Haematology, 2001, 113, 180-184.	2.5	94
274	Human immunodeficiency virus type 1 Tat binds to Candida albicans, inducing hyphae but augmenting phagocytosis in vitro. Immunology, 2001, 104, 455-461.	4.4	12
275	HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. FEMS Immunology and Medical Microbiology, 2001, 31, 65-71.	2.7	3
276	Evaluation of Inoculum Preparation for Etest and EUCAST Broth Dilution to Detect Anidulafungin Polyresistance in Candida glabrata. Antimicrobial Agents and Chemotherapy, 0, , .	3.2	0